Carcinoma, Ductal, Breast
"Carcinoma, Ductal, Breast" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
| Descriptor ID |
D018270
|
| MeSH Number(s) |
C04.557.470.200.025.232.500 C04.557.470.615.132.500 C04.588.180.390 C17.800.090.500.390
|
| Concept/Terms |
Carcinoma, Ductal, Breast- Carcinoma, Ductal, Breast
- Carcinoma, Invasive Ductal, Breast
- Invasive Ductal Carcinoma, Breast
- Carcinoma, Infiltrating Duct
- Carcinomas, Infiltrating Duct
Carcinoma, Mammary Ductal- Carcinoma, Mammary Ductal
- Carcinomas, Mammary Ductal
- Mammary Ductal Carcinomas
- Mammary Ductal Carcinoma
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Ductal, Breast".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Carcinoma [C04.557.470.200]
- Adenocarcinoma [C04.557.470.200.025]
- Carcinoma, Ductal [C04.557.470.200.025.232]
- Carcinoma, Ductal, Breast [C04.557.470.200.025.232.500]
- Neoplasms, Ductal, Lobular, and Medullary [C04.557.470.615]
- Carcinoma, Ductal [C04.557.470.615.132]
- Carcinoma, Ductal, Breast [C04.557.470.615.132.500]
- Neoplasms by Site [C04.588]
- Breast Neoplasms [C04.588.180]
- Carcinoma, Ductal, Breast [C04.588.180.390]
- Skin and Connective Tissue Diseases [C17]
- Skin Diseases [C17.800]
- Breast Diseases [C17.800.090]
- Breast Neoplasms [C17.800.090.500]
- Carcinoma, Ductal, Breast [C17.800.090.500.390]
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Ductal, Breast".
This graph shows the total number of publications written about "Carcinoma, Ductal, Breast" by people in this website by year, and whether "Carcinoma, Ductal, Breast" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2001 | 2 | 1 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 4 | 0 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 2 | 3 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 1 | 5 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 0 | 3 |
| 2022 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Ductal, Breast" by people in Profiles.
-
Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Feb; 32(2):922-930.
-
Nationwide Analysis of Locoregional Management for Ductal Carcinoma In Situ in Males: An NCDB Analysis of the Surgical Approach to DCIS in Males. Ann Surg Oncol. 2024 Mar; 31(3):1599-1607.
-
Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell. 2023 08 31; 186(18):3968-3982.e15.
-
HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series. Breast Cancer Res Treat. 2023 Jun; 199(2):349-354.
-
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell. 2022 12 12; 40(12):1521-1536.e7.
-
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041.
-
Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. Breast Cancer Res. 2022 10 18; 24(1):68.
-
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Res. 2022 10 17; 82(20):3673-3686.
-
Prognostic Impact of Radiation Therapy in Pure Mucinous Breast Carcinoma. Clin Breast Cancer. 2022 10; 22(7):e807-e817.
-
Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial. JAMA Surg. 2022 07 01; 157(7):573-580.